Bicycle Therapeutics (NASDAQ:BCYC) Stock: Insider Kevin Lee Sells 6,167 Shares

Key Points

• CEO Kevin Lee sold 6,167 Bicycle Therapeutics shares at an average price of $3.47, worth $21,399, to cover tax withholding on vested equity awards. He retained 597,504 shares afterward; he also sold 1,638 shares in a separate transaction.
• BCYC traded at $3.79, near its 12-month low of $3.33 and below its 50-day and 200-day moving averages. The company recently missed quarterly earnings and revenue expectations, while analysts forecast a full-year loss of $2.26 per share.
• Institutional investors own 86.15% of the stock, and analyst opinion is mixed: the consensus rating is Hold, with a $13.86 target price compared with the current share price.

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 6,167 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $3.47, for a total value of $21,399.49. Following the sale, the chief executive officer directly owned 597,504 shares in the company, valued at $2,073,338.88. This trade represents a 1.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, October 5th, Kevin Lee sold 1,638 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $3.57, for a total value of $5,847.66.

Bicycle Therapeutics Stock Performance

BCYC stock traded down $0.22 during trading on Tuesday, reaching $3.79. 620,678 shares of the company traded hands, compared to its average volume of 422,826. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $3.33 and a 12 month high of $9.16. The business has a 50 day simple moving average of $3.96 and a 200 day simple moving average of $4.31. The company has a market capitalization of $265.27 million, a price-to-earnings ratio of -1.39 and a beta of 1.68.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.14). Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%.The firm had revenue of $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. As a group, research analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BCYC. Armistice Capital LLC lifted its stake in shares of Bicycle Therapeutics by 8.7% during the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company's stock worth $22,911,000 after buying an additional 258,000 shares during the period. Renaissance Technologies LLC increased its position in shares of Bicycle Therapeutics by 72.8% in the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company's stock valued at $4,544,000 after acquiring an additional 412,700 shares during the period. Flax Pond Capital LLC purchased a new position in Bicycle Therapeutics in the 4th quarter worth $1,229,000. Fcpm Iii Services B.V. raised its stake in Bicycle Therapeutics by 0.5% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company's stock worth $24,556,000 after acquiring an additional 16,100 shares during the last quarter. Finally, FNY Investment Advisers LLC lifted its position in Bicycle Therapeutics by 247.4% during the 2nd quarter. FNY Investment Advisers LLC now owns 26,250 shares of the company's stock worth $111,000 after acquiring an additional 18,693 shares during the period. Institutional investors and hedge funds own 86.15% of the company's stock.

Analyst Ratings Changes

BCYC has been the subject of a number of analyst reports. Wall Street Zen raised shares of Bicycle Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Bicycle Therapeutics in a report on Wednesday, July 8th. Finally, Needham & Company LLC reduced their price target on Bicycle Therapeutics from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $13.86.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc NASDAQ: BCYC is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.